MedTrace Logo

Montelukast - a Treatment Choice for COVID-19

NCT04714515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-01-19

No results posted yet for this study

Summary

The current study aimed to make a therapeutic comparison and effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the standard of care. The safety and efficacy of HCQ and ML will be assessed as individual therapy and in combination with each other and with the standard of care. Cytokine storm (Interleukin levels) also will be monitored throughout the study to assess treatment progression.

Conditions

Interventions

DRUG

Montelukast

An FDA approved medicine to treat asthmatic patients

DRUG

Hydroxychloroquine

An FDA approved antiarthritis drug

DRUG

Ivermectin

An FDA approved anti-parasitic medicine

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Shaukat Khanum Memorial Cancer Hospital & Research Centre

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Teesside University

    collaborator OTHER

  • University of Sargodha

    lead OTHER

Principal Investigators

  • Wei Zhang, MD · Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China

  • Muhammad Rehman Akram, MBBS · Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2020-03-30
Completion
2020-04-20
FDA Drug
Yes

Countries

  • China
  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04714515 on ClinicalTrials.gov